Based on the success of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) and Ph+ ALL, there is potential for targeted JAK2 inhibitors to improve outcomes for patients with high-risk, JAK2-altered ALL. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.